So, you're looking at the Abbott Laboratories stock price and wondering if it's actually a deal or just a slow-mover. It’s currently hovering around $121.76 as of mid-January 2026. If you’ve been watching the ticker lately, you’ve seen it take a bit of a breather, dropping about 1.96% in the last week. Honestly, it’s been a weird few years for healthcare.
We’re finally out of that frantic COVID-testing era that sent diagnostics revenue through the roof. Now, Abbott (ABT) is trying to remind everyone that they are way more than just a rapid test company. You've got people like Lee Hambright over at Bernstein raising price targets to $154, while others are a bit more cautious. It’s a classic tug-of-war between "boring reliability" and "high-growth tech."
The "Boring" Dividend Magic
Let’s be real: most people buy Abbott because they want to sleep at night. They are a Dividend King. That’s not a title you get by accident; they’ve hiked that payout for 54 consecutive years. As of right now, the dividend sits at $0.63 per share quarterly. That gives you a yield of roughly 2.07%.
Is that going to make you a millionaire overnight? No. But in a volatile market, that kind of consistency is like a warm blanket. Most analysts, like the team at Barclays, are actually quite bullish, with some calling for a price target as high as $169. They see the 12.5% organic growth in Medical Devices and think the market is underpricing the "new" Abbott.
👉 See also: Who Owns Resorts World Las Vegas: What Most People Get Wrong
What’s Actually Moving the Abbott Laboratories stock price?
The biggest story right now isn't the pharmacy shelf; it's the tech on people's arms. Abbott’s FreeStyle Libre system is basically a money printer. We’re talking about $2 billion in sales just in the third quarter of 2025. People with diabetes are moving away from finger sticks, and Abbott is leading that charge with 17% growth in that segment alone.
But it’s not all sunshine. The stock has been fighting some "headline risk." There’s been ongoing litigation regarding infant formula (the NEC lawsuits), which acts like a lead weight on the share price every time a new court date pops up. Investors hate uncertainty. Even if the underlying business is humming along with a 31% net margin—which is frankly insane for a company this size—the legal shadow keeps some big institutional buyers on the sidelines.
The Competition is Heating Up
You can't talk about ABT without mentioning DexCom. While Abbott owns the "value" end of the continuous glucose monitor (CGM) market, DexCom is the high-end rival.
✨ Don't miss: Qué es un paraíso fiscal: Lo que las multinacionales y los gobiernos no quieren que sepas
- Abbott (ABT): Massive diversification. If heart valves are down, baby formula or generic drugs in India pick up the slack.
- DexCom (DXCM): Pure play. If CGM tech shifts, they have no safety net.
- Medtronic (MDT): The old-school rival. They’re stable but haven't shown the same "cool factor" growth as Abbott’s biowearables.
Why 2026 Feels Different
Wall Street is betting on a "normalized" year. We’ve finally lapped the massive COVID revenue drops. Now, the Abbott Laboratories stock price should, in theory, reflect the actual health of their core business.
One thing most people ignore is their Established Pharmaceuticals division. This isn't the stuff you see advertised on Super Bowl commercials. It’s a massive business selling branded generics in emerging markets like India, Brazil, and China. It grew 7% recently. While everyone is obsessed with AI and weight-loss drugs (looking at you, Eli Lilly), Abbott is quietly dominating the medicine cabinets of the global middle class.
The Bear Case (Because nothing is perfect)
If you’re a skeptic, you’re looking at the P/E ratio of about 15.2. That’s not exactly "cheap" for a company growing revenue in the high single digits. Some bears argue that the easy money in CGMs has been made and that insurance companies will start squeezing margins. Plus, the US dollar strength can be a total pain for a company that gets 60% of its cash from overseas.
Actionable Insights for Your Portfolio
If you're thinking about jumping in, here is how the pros are playing it right now:
- Watch the $113 Floor: The 52-week low is around $113. If it hits that level again without a fundamental disaster, it’s historically been a "buy the dip" zone.
- Check the Earnings Date: The next big catalyst will be the full-year 2025 wrap-up and 2026 guidance. If management stays "comfortable with consensus," the stock likely grinds higher.
- Dividend Reinvestment: Because of the steady growth, using a DRIP (Dividend Reinvestment Plan) on ABT has historically outperformed the S&P 500 over 20-year periods.
Basically, Abbott is a "core" holding. It’s the kind of stock you buy for your kid's college fund or your own retirement when you don't want to gamble on the next tech fad. It’s got a bit of growth, a bit of safety, and a lot of history. Just don't expect it to double in six months—that's not what this engine is built for.
Next Steps:
- Check your current portfolio allocation to healthcare; if you're under 10%, a diversified giant like Abbott often serves as a good anchor.
- Review the upcoming Q4 earnings report specifically for "Medical Device" organic growth—if this dips below 10%, the bull case weakens.
- Compare the current yield against the 10-year Treasury; when the gap narrows, ABT becomes a much more attractive "bond alternative."